Fosun Pharma: Subsidiary's Sodium Thiosulfate Injection Receives Registration Approval

MetaMuskRat · 2026-03-22T05:04:40+00:00

People Finance News, March 20 – Fosun Pharma (600196) announced on March 20 that its controlling subsidiary Chongqing Kaylin Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the drug registration application of sodium thiosulfate injection. The approved indication for this product is for the treatment of cyanide poisoning, and it can also be used for poisoning caused by arsenic, mercury, lead, bismuth, iodine, and other substances. Its controlling subsidiary Shanghai Fuhong Hengrui Biotechnology Co., Ltd. and its controlling subsidiaries received approval from the National Medical Products Administration to initiate Phase I clinical trials of HLX18 (recombinant anti-PD-1 humanized monoclonal antibody injection) for the treatment of multiple solid tumors.

MetaMuskRat

2026-03-22 05:04:40

People’s Financial News, March 20 — Fosun Pharma (600196) announced on March 20 that its controlling subsidiary, Chongqing Kailin Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration application of sodium thiosulfate injection. The approved indication is for cyanide poisoning, and it can also be used for poisoning by arsenic, mercury, lead, bismuth, iodine, and other substances. The controlling subsidiary, Shanghai Fosun Hanlin Biotech Co., Ltd., and its subsidiaries received approval from the National Medical Products Administration to conduct Phase I clinical trials of HLX18 (a recombinant anti-PD-1 humanized monoclonal antibody injection) for the treatment of various solid tumors.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.